Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.10.0.1
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following tables summarize, for the periods indicated, operating results by reportable segment:
  
Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold.
 
($ in thousands)
Three Months Ended September 30, 2018
 
Dermatology
Products
Sales
 
 
Pharmaceutical
and
Biotechnology
Product
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
5,168
 
 
$
5
 
 
$
58,520
 
 
$
63,693
 
Direct cost of goods
 
 
(1,406
)
 
 
–
 
 
 
-
 
 
 
(1,406
)
Sales and marketing costs
 
 
(2,754
)
 
 
–
 
 
 
–
 
 
 
(2,754
)
Research and development
 
 
–
 
 
 
(19,788
)
 
 
–
 
 
 
(19,788
)
General and administrative
 
 
(505
)
 
 
(8,925
)
 
 
–
 
 
 
(9,430
)
National expenses
 
 
–
 
 
 
–
 
 
 
(55,204
)
 
 
(55,204
)
Segment income (loss) from operations
 
$
503
 
 
$
(28,708
)
 
$
3,316
 
 
$
(24,889
)
Segment assets
 
$
10,765
 
 
$
157,781
 
 
$
56,373
 
 
$
224,919
 
 
 
 
Dermatology
 
 
Pharmaceutical
and
Biotechnology
 
 
 
 
 
 
 
($ in thousands)
 
Products
 
 
Product
 
 
 
 
 
 
 
Three Months Ended September 30, 2017
 
Sales
 
 
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
2,170
 
 
$
350
 
 
$
44,366
 
 
$
46,886
 
Direct cost of goods
 
 
(505
)
 
 
–
 
 
 
–
 
 
 
(505
)
Sales and marketing costs
 
 
(2,786
)
 
 
–
 
 
 
–
 
 
 
(2,786
)
Research and development
 
 
–
 
 
 
(16,190
)
 
 
–
 
 
 
(16,190
)
General and administrative
 
 
(349
)
 
 
(11,969
)
 
 
–
 
 
 
(12,318
)
National Expenses
 
 
–
 
 
 
–
 
 
 
(47,690
)
 
 
(47,690
)
Segment loss from operations
 
$
(1,470
)
 
$
(27,809
)
 
$
(3,324
)
 
$
(32,603
)
Segment assets
 
$
7,362
 
 
$
160,038
 
 
$
77,691
 
 
$
245,091
 
 
($ in thousands)
Nine Months Ended September 30, 2018
 
Dermatology
Products
Sales
 
 
Pharmaceutical
and
Biotechnology
Product
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
17,366
 
 
 
525
 
 
$
165,061
 
 
$
182,952
 
Direct cost of goods
 
 
(4,546
)
 
 
–
 
 
 
–
 
 
 
(4,546
)
Sales and marketing costs
 
 
(8,443
)
 
 
–
 
 
 
–
 
 
 
(8,443
)
Research and development
 
 
–
 
 
 
(62,332
)
 
 
–
 
 
 
(62,332
)
General and administrative
 
 
(1,270
)
 
 
(29,075
)
 
 
–
 
 
 
(30,345
)
National expenses
 
 
–
 
 
 
–
 
 
 
(162,258
)
 
 
(162,258
)
Segment income (loss) from operations
 
$
3,107
 
 
$
(90,882
)
 
$
2,803
 
 
$
(84,972
)
Segment assets
 
$
10,765
 
 
$
157,781
 
 
 $
56,373
 
 
$
224,919
 
 
 
 
Dermatology
 
 
Pharmaceutical
and
Biotechnology
 
 
 
 
 
 
 
($ in thousands)
 
Products
 
 
Product
 
 
 
 
 
 
 
Nine Months Ended September 30, 2017
 
Sales
 
 
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
8,309
 
 
$
1,393
 
 
$
132,563
 
 
$
142,265
 
Direct cost of goods
 
 
(1,852
)
 
 
–
 
 
 
–
 
 
 
(1,852
)
Sales and marketing costs
 
 
(7,663
)
 
 
–
 
 
 
–
 
 
 
(7,663
)
Research and development
 
 
–
 
 
 
(38,077
)
 
 
–
 
 
 
(38,077
)
General and administrative
 
 
(961
)
 
 
(27,866
)
 
 
–
 
 
 
(28,827
)
National Expenses
 
 
–
 
 
 
–
 
 
 
(139,219
)
 
 
(139,219
)
Segment loss from operations
 
$
(2,167
)
 
$
(64,550
)
 
$
(6,656
)
 
$
(73,373
)
Segment assets
 
$
7,362
 
 
$
160,038
 
 
$
77,691
 
 
$
245,091